Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

CHRS - Coherus Oncology, Inc. So'nggi Yangiliklar | Finranks

Home

/

CHRS

C

Coherus Oncology, Inc. (CHRS)

NGM – Real vaqt narxi. Valyuta: USD

1.71

-0.24 (-12.31%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.77

+0.06 (3.51%)

Bozor oldidan: May 13, 2026, 5:59 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.

Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know

Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif.

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company's common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.